Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts. more
Time Frame | AKTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 16.07% | -0.09% | 0.83% |
1-Month Return | -46.49% | 0.03% | 5.98% |
3-Month Return | -64.48% | -6.26% | 9.65% |
6-Month Return | -32.64% | 1.16% | 14.29% |
1-Year Return | -59.88% | 11.16% | 32.26% |
3-Year Return | -95.7% | 11.98% | 31.61% |
5-Year Return | -96.67% | 47.19% | 94.03% |
10-Year Return | -99.88% | 109.06% | 191.47% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 19.20K | 8.91K | 4.13K | 3.71K | 4.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":46.38,"profit":true},{"date":"2021-12-31","value":21.48,"profit":true},{"date":"2022-12-31","value":19.31,"profit":true},{"date":"2023-12-31","value":20.83,"profit":true}] |
Gross Profit | (19.20K) | (8.91K) | (4.13K) | (3.71K) | (4.00K) | [{"date":"2019-12-31","value":-1920500,"profit":false},{"date":"2020-12-31","value":-890700,"profit":false},{"date":"2021-12-31","value":-412600,"profit":false},{"date":"2022-12-31","value":-370800,"profit":false},{"date":"2023-12-31","value":-400000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | - | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 24.89M | 20.10M | 17.21M | 23.89M | 16.81M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":80.77,"profit":true},{"date":"2021-12-31","value":69.16,"profit":true},{"date":"2022-12-31","value":95.99,"profit":true},{"date":"2023-12-31","value":67.52,"profit":true}] |
Operating Income | (24.87M) | (17.98M) | (17.21M) | (23.09M) | (16.81M) | [{"date":"2019-12-31","value":-2487000000,"profit":false},{"date":"2020-12-31","value":-1798097400,"profit":false},{"date":"2021-12-31","value":-1721413600,"profit":false},{"date":"2022-12-31","value":-2308820800,"profit":false},{"date":"2023-12-31","value":-1680600000,"profit":false}] |
Total Non-Operating Income/Expense | 122.53K | 912.97K | (199.50K) | 5.39M | - | [{"date":"2019-12-31","value":2.28,"profit":true},{"date":"2020-12-31","value":16.95,"profit":true},{"date":"2021-12-31","value":-3.7,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (24.75M) | (20.45M) | (17.42M) | (17.75M) | (10.01M) | [{"date":"2019-12-31","value":-2475300000,"profit":false},{"date":"2020-12-31","value":-2045400000,"profit":false},{"date":"2021-12-31","value":-1742423700,"profit":false},{"date":"2022-12-31","value":-1774806200,"profit":false},{"date":"2023-12-31","value":-1000800000,"profit":false}] |
Income Taxes | (2.99M) | (2.86M) | 182.62K | (10.78M) | - | [{"date":"2019-12-31","value":-1636.74,"profit":false},{"date":"2020-12-31","value":-1564.46,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-5900.71,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (21.76M) | (17.60M) | (17.61M) | (6.97M) | - | [{"date":"2019-12-31","value":-2176400000,"profit":false},{"date":"2020-12-31","value":-1759700000,"profit":false},{"date":"2021-12-31","value":-1760685600,"profit":false},{"date":"2022-12-31","value":-697225200,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (17.11M) | (17.08M) | (17.42M) | (17.75M) | - | [{"date":"2019-12-31","value":-1710579100,"profit":false},{"date":"2020-12-31","value":-1708161700,"profit":false},{"date":"2021-12-31","value":-1742423700,"profit":false},{"date":"2022-12-31","value":-1774806200,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (21.76M) | (17.60M) | (17.61M) | (6.97M) | (10.01M) | [{"date":"2019-12-31","value":-2176400000,"profit":false},{"date":"2020-12-31","value":-1759700000,"profit":false},{"date":"2021-12-31","value":-1760685600,"profit":false},{"date":"2022-12-31","value":-697225200,"profit":false},{"date":"2023-12-31","value":-1000800000,"profit":false}] |
EPS (Diluted) | (0.93) | - | - | (0.90) | - | [{"date":"2019-12-31","value":-93,"profit":false},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-89.56,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
AKTX | |
---|---|
Cash Ratio | 0.24 |
Current Ratio | 0.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AKTX | |
---|---|
ROA (LTM) | -172.83% |
ROE (LTM) | -1281.43% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AKTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 3.45 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -2.45 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AKTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 3.07 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Akari Therapeutics PLC (AKTX) share price today is $1.3
Yes, Indians can buy shares of Akari Therapeutics PLC (AKTX) on Vested. To buy Akari Therapeutics PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AKTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Akari Therapeutics PLC (AKTX) via the Vested app. You can start investing in Akari Therapeutics PLC (AKTX) with a minimum investment of $1.
You can invest in shares of Akari Therapeutics PLC (AKTX) via Vested in three simple steps:
The 52-week high price of Akari Therapeutics PLC (AKTX) is $4.4. The 52-week low price of Akari Therapeutics PLC (AKTX) is $0.9.
The price-to-earnings (P/E) ratio of Akari Therapeutics PLC (AKTX) is
The price-to-book (P/B) ratio of Akari Therapeutics PLC (AKTX) is 3.07
The dividend yield of Akari Therapeutics PLC (AKTX) is 0.00%
The market capitalization of Akari Therapeutics PLC (AKTX) is $30.35M
The stock symbol (or ticker) of Akari Therapeutics PLC is AKTX